NOAC Dosing for Acute Pulmonary Embolism
For acute PE, use rivaroxaban 15 mg twice daily with food for 21 days, then 20 mg once daily, or apixaban 10 mg twice daily for 7 days, then 5 mg twice daily—both allow immediate oral treatment without parenteral bridging. 1
Initial Treatment Regimens
Single-Drug Regimens (No Parenteral Lead-In Required)
Rivaroxaban:
- 15 mg twice daily with food for 21 days
- Then 20 mg once daily with food for maintenance 1, 2
- Must be taken with food to ensure adequate absorption 1
Apixaban:
Regimens Requiring Parenteral Lead-In
Dabigatran:
- LMWH ≥5 days first
- Then 150 mg twice daily 1
Edoxaban:
- LMWH ≥5 days first
- Then 60 mg once daily 1
Renal Function Adjustments
Rivaroxaban
| Creatinine Clearance | Dose |
|---|---|
| ≥50 mL/min | 15 mg BID × 21 days → 20 mg daily [3] |
| 30-49 mL/min | 15 mg BID × 21 days → 15 mg daily [3] |
| 15-29 mL/min | 15 mg daily [3] |
| <15 mL/min | Avoid [1] |
Apixaban
For VTE treatment, the "2-of-3" dose-reduction rule used in atrial fibrillation does NOT apply 4
Standard VTE dosing regardless of renal function:
Edoxaban
Standard dose: 60 mg once daily 1
Reduce to 30 mg once daily if:
- CrCl 30-50 mL/min, OR
- Body weight <60 kg 1
Dabigatran
- 150 mg twice daily is standard 1
- Reduce to 110 mg twice daily if CrCl 30-49 mL/min in Europe (not FDA-approved in US for this indication) 1
- Contraindicated if CrCl <30 mL/min 1
Calculating Renal Function
Use the Cockcroft-Gault equation with actual body weight—this is what the pivotal trials used and what FDA labeling is based on 4
Do not use eGFR for NOAC dosing decisions 4
Comparative Renal Clearance
Understanding renal dependence helps guide selection in borderline renal function:
| NOAC | Renal Clearance |
|---|---|
| Apixaban | ~27% [4] |
| Rivaroxaban | ~35-66% [4] |
| Edoxaban | ~50% [4] |
| Dabigatran | ~80% [1,4] |
Apixaban has the lowest renal dependence, making it the safest choice as kidney function declines 4
Practical Selection Algorithm
Step 1: Calculate CrCl using Cockcroft-Gault
Step 2: Choose based on renal function:
CrCl ≥50 mL/min: Any NOAC is appropriate
- Prefer rivaroxaban or apixaban to avoid parenteral lead-in 1
CrCl 30-49 mL/min:
CrCl 15-29 mL/min:
CrCl <15 mL/min or dialysis:
Step 3: Screen for drug interactions
- Avoid rivaroxaban and apixaban with strong dual CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir, itraconazole) 4, 3
- Avoid all NOACs with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) 4
Monitoring Requirements
Renal function:
No routine INR monitoring required 4
Monitor for bleeding symptoms, particularly gastrointestinal 4
Common Prescribing Errors to Avoid
Do not apply atrial fibrillation dose-reduction criteria to VTE treatment—the "2-of-3" rule (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) does NOT apply to PE dosing 4
Do not use eGFR instead of Cockcroft-Gault CrCl—this leads to dosing errors 4
Do not underdose rivaroxaban based on perceived bleeding risk alone—inappropriate dose reduction is common and increases thrombotic risk 5
Do not forget food requirement for rivaroxaban—absorption is significantly reduced without food 1, 3
Efficacy and Safety Evidence
All four NOACs demonstrated non-inferiority to LMWH/warfarin for recurrent VTE 1
Bleeding outcomes:
- Rivaroxaban: Major bleeding 1.1% vs 2.2% with warfarin (HR 0.49) 2
- Apixaban: Major bleeding 0.6% vs 1.8% with warfarin 1
- All NOACs showed lower or similar major bleeding rates compared to warfarin 1
Hospital length of stay is significantly shorter with single-drug NOACs (rivaroxaban, apixaban) compared to LMWH/warfarin bridging 1